



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

January 16, 2024

Thomas Meyer  
Chief Executive Officer  
Altamira Therapeutics Ltd.  
8 The Green  
Suite 12455  
Dover, DE 19901

**Re: Altamira Therapeutics Ltd.**  
**Registration Statement on Form F-3**  
**Filed January 8, 2024**  
**File No. 333-276427**

Dear Thomas Meyer:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Tamika Sheppard at 202-551-8346 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Michael Lerner